Synthesis, and In-vitro Antibacterial Activity Studies of Characterization Oxovanadium (IV) Complexes of α-Amino Acid Schiff Bases and 1,10-Phenanthroline Ligands

Abstract

Oxovanadium(IV) complexes of the type [VO(L)(phen)], where phen is 1,10-phenanthtroline, and L= N-salicylidene-β-alanine (sal-ala), N-salicylidene-glycine (sal-gly), N-salicylidene-DL-β-phenylalanine (sal-pheala), N-salicylidene-leucine (sal-leu), and N-salicylidene-DL-methionine (sal-met), have been synthesized and characterized by FTIR and UV-Vis spectra, molar conductance, and magnetic susceptibilities measurements of the compounds. The infrared spectrum data show that the amino acid-based Schiff base ligand is tridentate, and that it is coordinated with vanadyl (VO^{2+}) ions via azomethine nitrogen, phenolic oxygen, and carboxylate oxygen. Conductivity measurements revealed that all complexes are not electrolytes. Magnetic moment studies have shown that these complexes are paramagnetic in nature and have the d^1 configuration of the vanadium (IV) ion. The antibacterial efficacy of the produced complexes was investigated against four pathogenic bacteria, namely *Escherichia coli*, *Proteus vulgaris*, *Bacillus subtilis* and *Staphylococcus aureus*. Among all synthesized complexes, [VO(sal-leu)(bpy)], also known as VO-3, displayed good and greater antibacterial activity than Streptomycin (10 µg/disc) against all pathogens.

Keywords: α-Amino Acid; Oxovanadium (IV) complexes**;** Schiff base; 1,10-phenanthroline.

Graphical abstract :



Figure 4.1 Graphical representation of antibacterial activity of oxovanadium (IV) complexes

1. Introduction

Schiff base complexes of amino acids have garnered a significant amount of attention in recent years due to the physiological and pharmacological activity that they exhibit [1,2]. Schiff bases maintain a significant role in metal coordination chemistry as they facilitate the incorporation of transition metals. This is attributed to their ability to serve as ligands, forming stable complexes with metal ions. This phenomenon leads to an elevation in the ligand's biological activity and a reduction in the cytotoxic impacts of the metal ion and ligand upon the host [3].

In the past decade, numerous vanadium complexes featuring organic chelating ligands have undergone evaluation in animal and cell models, aiming to enhance both absorption and tissue uptake [4,5]. Vanadium possesses biological, medicinal [6], and pharmacological [7] significance in different forms [8,9]. The coordination chemistry of vanadium has garnered considerable interest owing to the use of diverse vanadium complexes as templates for understanding the biological roles of vanadium [10-13]. These roles encompass a spectrum of activities, including antimicrobial [14], antitumor [15], antioxidant [16], and anti-diabetic properties [17,18]. Additionally, vanadium complexes have been implicated in nitrogen fixation [19], phosphorylation [20], insulin mimicking [21-25], haloperoxidation [26], inhibition of tumor growth, and prevention of carcinogenesis [27]. Furthermore, high-valent vanadium complexes are being explored as innovative catalytic reagents in various oxidation reactions [28,29], such as olefin oxidation [30,31], sulfides [34,35], benzene/alkyl aromatic compounds [32,33], and alcohols [36-38]. Due to their potential applications, vanadium complexes have garnered significant attention in interdisciplinary research, especially regarding their synthesis and design for addressing various medical conditions [39, 40]. The configuration of the oxovanadium (IV) complex is greatly influenced by the chelating abilities of its ligands, as demonstrated in existing literature [41]. Based on reports, Schiff bases demonstrate the capacity to establish stable complexes with vanadium, commonly featuring coordination numbers ranging from four to six. [42]. Four and five-coordinate complexes may display geometries such as distorted square pyramidal, or distorted trigonal bipyramidal, square pyramidal arrangements. Regarding six-coordinate complexes, distorted octahedral structures have been observed, typically with an oxygen atom occupying the apical position. [43–45].

We recently conducted a study where we synthesized and characterized five new mixed ligand oxovanadium complexes. These complexes contained a Schiff base derived from salicylaldehyde and different amino acids (N-salicylidene-β-alanine, N-salicylidene-glycine, N-salicylidene-leucine, N-salicylidene-DL-β-phenylalanine, and N-salicylidene-DL-methionine) along with 1,10-phenanthroline. We then tested the antimicrobial activities of these complexes against pathogenic bacteria including Escherichia coli, Proteus vulgaris, Bacillus subtilis, and Staphylococcus aureus in a laboratory setting.

2. Experimental Methods

All chemicals and solvents were reagent grade and were used as received without further purification. The amino acid-based Schiff base tridentate ligands were synthesized according to published literature. The polypyridyl ligands 1,10-phenanthroline are commercially available. These complexes were synthesized by the template method.

Infrared spectra were recorded on a FTIR-8400, SHIMADZU, Japan using a KBr disc, at the Central Science Lab of Rajshahi University, UV-visible spectra of complexes were recorded on a SHIMADZU DOUBLE BEAM spectrophotometer (model UV-1200) at the Department of Chemistry, Rajshahi University. The melting points or decomposition temperature of all the prepared metal complexes were observed with an electrothermal melting point apparatus. It was, however, not possible to measure the melting points beyond 300^{o}C. The conductance measurements were made at room temperature using a WPACM35 conductivity meter and a dip-cell with a platinized electrode. The SHERWOOD SCIENTIFIC magnetic susceptibility balance was used to probe the magnetic nature of the complexes.

2.1 Procedure for the Synthesis of the complexes

2.2.1 Preparation of [VO(sal-ala)(phen)], (VO-1)

For the preparation of oxovanadium (IV) complexes, a round bottom flask containing a methanolic solution of salicylaldehyde (sal) (0.3 mL, 3 mmol) was filled with a mixture of α-amino acids, β-alanine (ala) (0.267 g, 3 mmol), and NaOH (0.100 g, 2.25 mmol) in 10 mL methanol. After refluxing the resultant solution for an hour, vanadyl sulphate (0.489 g, 3 mmol) was added in a methanolic solution. After refluxing the mixture for an hour, a pale blue precipitate formed. To this mixture 1,10-phenanthroline (phen) (0.595 g, 3 mmol) taken in 10 mL of methanol was added. The solution on further refluxing for 1 hour gave a red

precipitate. The precipitate was filtered off on a Buchner funnel, washed with methanol and finally dried in a vacuum desiccator over anhydrous $CaCl_2$. [46]

Complexes V0-**2** to VO-**5** were prepared by the procedure as described for complex VO-**1** using DL-β-phenylalanine (phyala) (0.495 g, 3 mmol); leucine (leu) (0.393 g, 3 mmol); glycine (gly) (0.225 g, 3 mmol); DL-methionine (met) (0.448 g, 3 mmol) respectively instead of β-alanine (ala).



Scheme 1: Preparation of the proposed Oxovanadium complexes, VO-1 to VO-5

2.1.2 Physical, Analytical and Spectral Data of synthesized complexes, VO-1 to VO-5

[VO(sal-ala)(phen)], (VO-1)

Yield: 0.912 g (69%) Λ_M = 17.6 $ohm^{-1}\ cm^2\ mol^{-1}$ in DMF at 31 °C. IR (KBr phase, cm^{-1}): 3434br, 1625s, 1542s (C=N), 1318m, 965s (V=O), 623s, 460m (br, broad; vs, very strong; s, strong; m, medium; w, weak). UV-Vis (DMSO), λ/nm (ε/$M^{-1}\ cm^{-1}$): 266–306 (3215–3325), 364 (2709), 384sh (2647), 462 (329) (sh, shoulder). μ_{eff} =1.89 B.M. at 303 K. Elemental analysis (%): Calculated (Found): C: 60.28 (60.20), H: 3.91(3.74), N: 9.59(9.45), O: 14.60(14.48).

[VO(sal-pheala)(phen)], (VO-2)

Yield: 1.102 g (71%) Λ_M = 16.3 $ohm^{-1}\ cm^2\ mol^{-1}$ in DMF at 31 °C. IR (KBr phase, cm^{-1}): 3429br, 1620s, 1540s (C=N), 1310w, 956s (V=O), 619s, 446m. UV-Vis (DMSO), λ/nm (ε/$M^{-1}\ cm^{-1}$): 264–291 (3414–3311), 322 (469), 383sh (2647), 458 (96). μ_{eff} =1.56 B.M. at

303 K. Elemental analysis (%): Calculated (Found): C: 65.37 (65.12), H: 4.11(4.01), N: 8.17(8.10), O: 12.44(14.32)

[VO(sal-leu)(phen)], (VO-3)

Yield: 0.989 g (68%) Λ_M = 15.1 ohm^{-1} cm^2 mol^{-1} in DMF at 31 °C. IR (KBr phase, cm^{-1}): 3425br, 1651m, 1535m (C=N), 1326w, 963s (V=O), 619m, 453w. UV-Vis (DMSO), λ/nm (ε/M^{-1} cm^{-1}): 273−304 (3957−3675), 364 (2094), 388sh (2402), 456 (350). μ_{eff} =1.51 B.M. at 303 K. Elemental analysis (%): Calculated (Found): C: 61.54 (61.20), H: 4.95(4.68), N: 8.97(8.75), O: 13.66(13.48).

[VO(sal-gly)(phen)], (VO-4)

Yield: 0.644 g (50%) Λ_M = 16.6 ohm^{-1} cm^2 mol^{-1} in DMF at 31 °C. IR (KBr phase, cm^{-1}): 3382br, 1625m (C=N), 1535w, 1315w, 1107w, 960m (V=O), 849s, 618w, 440w. UV-Vis (DMSO), λ/nm (ε/M^{-1} cm^{-1}): 267−304 (3263−3374), 361 (1747), 383sh (2069), 466 (266). μ_{eff} =1.60 B.M. at 303 K. Elemental analysis (%): Calculated (Found): C: 58.26 (58.12), H: 3.67(3.54), N: 10.19(10.10), O: 15.52(15.32).

[VO(sal-met)(phen)], (VO-5)

Yield: 0.966 g (64%) Λ_M = 8.1 ohm^{-1} cm^2 mol^{-1} in DMF at 31 °C. IR (KBr phase, cm^{-1}): 3401br, 1618s, 1535s (C=N), 1310m, 960vs (V=O), 618m, 449m. UV-Vis (DMSO), λ/nm (ε/M^{-1} cm^{-1}): 269−306 (3325−3436), 362 (2874), 396sh (2937), 475 (564). μ_{eff} =1.89 B.M. at 303 K.

3. Results and Discussion

For the purpose of determining the formation of the complexes, a variety of methods are utilized. These techniques include magnetic susceptibility, conductivity evaluation, infrared spectra, and ultraviolet-visible spectra.

3.1 Physical Properties

All the complexes of oxovanadium (IV), (**VO-1 to VO-5**) are soluble in DMF and DMSO but insoluble in common organic solvents such as methanol, ethanol, benzene, chloroform. The molar conductance of the complexes measured in DMF at 10^{-3} M concentration fall in the range of 8.1 to 17.6 Ω^{-1} cm^2 mol^{-1}. These values are lower than expected for an electrolyte. Thus, molar conductance values indicate that the complexes are non-electrolyte in nature as expected. [47] The magnetic moments of complexes were in the range 1.51–1.89 B.M., which correspond to a single electron of the d^1 system of oxovanadium (IV) center and paramagnetic in nature. [48]

Table 1 Physical Properties of the prepared oxovanadium (IV) complexes

Symbol	**Complex**	**Color**	**Melting point or Decomposition** /ºC	**Solubility**		**Conductivity** ohm^{-1} cm^2 mol^{-1}	**μ_{eff} in B.M**
				DMF	**DMSO**		
VO-1	[VO(sal-ala)(phen)]	Orange	230–233 (de)	+ve	+ve	17.6	1.89
VO-2	[VO(sal-pheala)(phen)]	Orange	199–202 (de)	+ve	+ve	16.3	1.56
VO-3	[VO(sal-leu)(phen)]	Red	263–267(de)	+ve	+ve	15.1	1.51
VO-4	[VO(sal-gly)(phen)]	Blackish red	210–212 (de)	+ve	+ve	16.6	1.60
VO-5	[VO(sal-met)(phen)]	Red	258–261 (de)	+ve	+ve	8.1	1.89

3.2 IR spectral studies

The infrared spectral analysis of oxovanadium (IV) complexes reveals a broad band ranging from 3382 to 3429 cm^{-1}, indicative of the probable existence of a water molecule in a hydrated state within the complexes. [49] There are ν (C=O) bands at 1618-1652 cm^{-1} and ν(C-O) bands at 1310-1326 cm^{-1} in the complexes, however these bands are much weaker than the ones seen in uncoordinated amino acids. In addition, the presence of ν(V–O) modes at approximately 618 cm-1 ensures that the carboxylate ion is coordinated with the central metal ion. [50] The absence of the ν(O–H) band typically observed around 3600 cm^{-1} for the

phenolic –OH group in these complexes suggests the coordination of the phenolic oxygen with the vanadyl ion. The bands observed at approximately 1540 cm^{-1} could potentially be attributed to the stretching frequency of ν(C=N), which would indicate that the azomethine nitrogen and heterocyclic nitrogen are coordinated with the VO^{2+} moiety. The coordination of the azomethine nitrogen and the nitrogen from heterocyclic groups is additionally supported by the presence of ν(V-N) modes in the region of 440-461 cm^{-1}. [51]

The present oxovanadium (IV) complexes exhibit the ν(V=O) stretching frequency in the 957–965 cm^{-1} region characteristic of metal-oxygen multiple bond, thus ruling out the possibility of polymeric nature of the complexes since the polymeric oxovanadium (IV) complexes exhibit one or more broad absorption bands below 900 cm^{-1} due to bridging vanadyl group, –V–O–V–. [52] The present complexes exhibit medium intense band in the region ~960 cm^{-1} indicating the monomeric nature of the complexes. [53] The IR spectra of oxovanadium (IV) complexes (**VO-1 to VO-5**) are shown in the Figures **1-5.**

Table 2Important IR frequencies of complexes (VO-1 to VO-5)

Symbol	**Complex**	**ν(OH)** cm^{-1}	**ν(C=O)** cm^{-1}	**ν(C–O)** cm^{-1}	**ν(C=N)** cm^{-1}	**ν(V–N)** cm^{-1}	**ν(V–O)** cm^{-1}	**ν(V=O)** cm^{-1}
VO-1	[VO(sal-ala)(phen)]	3434	1625	1318	1542	461	622	965
VO-2	[VO(sal-pheala)(phen)]	3429	1621	1310	1540	446	619	957
VO-3	[VO(sal-leu)(phen)]	3425	1652	1326	1535	453	618	964
VO-4	[VO(sal-gly)(phen)]	3382	1626	1315	1535	440	618	960
VO-5	[VO(sal-met)(phen)]	3401	1618	1310	1535	449	617	960



Figure 1 IR spectrum of [VO(sal-ala)(phen)] complex



Figure 2 IR spectrum of [VO(sal-pheala)(phen)] complex



Figure 3 IR spectrum of [VO(sal-leu)(phen)] complex



Figure 4 IR spectrum of [VO(sal-gly)(phen)] complex



Figure 5 IR spectrum of [VO(sal-met)(phen)]complex

3.3 UV-Visible spectral analysis

At wavelengths between 200 and 800 nm, the complexes' absorption spectra were recorded in DMSO. The complexes VO-1 to VO-5 display a shoulder at around 385 nm, which can be attributed to a ligand-to-metal charge-transfer (LMCT, $PhO^{-}\rightarrow V$) transition. The remaining bands in the ultraviolet region are indicative of intra-ligand transitions. [54] The $\pi\rightarrow\pi^*$ transition can be attributed to the bands observed at 264–306 nm in all compounds. [55] In addition, complexes have a relatively low intensity band at approximately 460 nm, which can be attributed to the transitions between d-d transitions. UV-Visible spectra of the complexes (**VO-1 to VO-5**) are given in the Figures **6 – 10**.

Table 3 Important UV-Visible spectra of complexes (VO-1 to VO-5)

Symbol	Complex	λ, nm (ε, M^{-1} cm^{-1})			
VO-1	[VO(sal-ala)(bpy)]	266−306 (3215−3325)	364 (2709)	384sh (2647)	462 (329)
VO-2	[VO(sal-pheala)(bpy)]	264−291 (3414−3311)	322 (469)	383sh (874)	458 (96)
VO-3	[VO(sal-leu)(bpy)]	273−304 (3662−3325)	364 (2094)	388sh (2402)	456 (350)

VO-4	[VO(sal-gly)(bpy)]	267−304 (3263−3374)	361 (1747)	383sh (2069)	460 (266)
VO-5	[VO(sal-met)(bpy)]	269−306 (3325−3436)	362 (2874)	396sh (2937)	475 (564)



Figure 6 UV-Visible spectrum of [VO(sal-ala)(phen)] complex



Figure 7 UV-Visible spectrum of [VO(sal-pheala)(phen)] complex



Figure 8 UV-Visible spectrum of [VO(sal-leu)(phen)] complex



Figure 9 UV-Visible spectrum of [VO(sal-gly)(phen)] complex



Figure 10 UV-Visible spectrum of [VO(sal-met)(phen)] complex

Based on the above characterization the presumptive structure of our synthesized complexes may be:



Figure 11 Probable structure of [VO(sal-met)(phen)] complex

4. Antibacterial Activity

The antibacterial activities of the ten oxovanadium (IV) complexes were screened at the concentration of 10 µg/disc against four pathogenic bacteria viz. *Escherichia coli*, *Proteus vulgaris*, *Bacillus subtilis* and *Staphylococcus aureus*. The results obtained were compared

with the inhibition of the standard antibiotic, streptomycin (10 µg/disc). The results are shown in the Table **4.** The complexes **VO-1 to VO-5** were found to be active against all the test bacteria, with the complexes **VO-3** being even more potent than the standard against all the bacteria except for *Escherichia coli*. The activity of the complexes **VO-3** against *Escherichia coli* are comparable with the standard. The remaining complexes **VO-1**, **VO-2**, **VO-4** and **VO-5** were active with low to moderate potency against all pathogenic bacteria and in comparison, of the result of the zones of inhibition of these complexes with that of the standard, streptomycin, their activities were lower than that of standard. It may thus be concluded that the suitable choice of organic ligands coordinated to the VO^{2+} moiety influences the antibacterial activity of the individual complexes. The antimicrobial activity of the complexes may be described on the basis of their effective interaction with the microbes which cause discrete and distinct types of injuries to microbial cells as a result of oxidative stress, protein dysfunction or membrane damage. More research is needed to carry out to disclose the activity and structure relationship.

Table 4. Antibacterial activities of the oxovanadium (IV) complexes and streptomycin.

Bacterial strains		**Zone if inhibition, diameter in mm**					
		VO-1 10 µg/disc	**VO-2 10 µg/disc**	**VO-3 10 µg/disc**	**VO-4 10 µg/disc**	**VO-5 10 µg/disc**	**Streptomycin 10 µg/disc**
Gram positive	***Bacillus subtilis***	**5**	**8**	**28**	**8**	**7**	**19**
	Staphylococcus aureus	**6**	**7**	**27**	**10**	**9**	**19**
Gram negative	***Escherichia coli***	**5**	**6**	**16**	**7**	**7**	**19**
	Proteus vulgaris	**5**	**7**	**24**	**5**	**7**	**19**



Figure 12 Graphical representation of antibacterial activity of oxovanadium (IV) complexes

Conclusion

The VO^{2+} complexes of *O*, *N*, *O*-donor α-amino acid Schiff bases and 1,10-phenanthroline have been synthesized and characterized. The analytical data reveal that the complexes are non-electrolytic and paramagnetic in nature. The magnetic moment values of the complexes are in accordance with the d^1 electronic configuration of the $V^{IV}O^{2+}$ moiety. Therefore, the structure of the complexes (**VO-1 to VO-5**) may be assigned as distorted octahedral geometry with VO_3N_3 coordination environment on the basis of physical and spectroscopic data.

Disclaimer (Artificial intelligence)

Option 1:

Author(s) hereby declare that NO generative AI technologies such as Large Language Models (ChatGPT, COPILOT, etc.) and text-to-image generators have been used during the writing or editing of this manuscript.

References

[1] Tai, A. W., Lien, E. J., Lai, M. M., & Khwaja, T. A.. Novel N-hydroxyguanidine derivatives as anticancer and antiviral agents. Journal of medicinal chemistry. 1984; 27(2), 236-238.

[2] Wang, P. H., Keck, J. G., Lien, E. J., & Lai, M. M.. Design, synthesis, testing, and quantitative structure-activity relationship analysis of substituted salicylaldehyde Schiff bases of 1-amino-3-hydroxyguanidine tosylate as new antiviral agents against coronavirus. Journal of medicinal chemistry. 1990; 33(2), 608-614.

[3] Trávníček, Z., Maloň, M., Šindelář, Z., Doležal, K., Rolčík, J., Kryštof, V., ... & Marek, J.. Preparation, physicochemical properties and biological activity of copper (II) complexes with 6-(2-chlorobenzylamino) purine (HL1) or 6-(3-chlorobenzylamino) purine (HL2). The single-crystal X-ray structure of [Cu (H+ L2)$_2$Cl$_3$] Cl· 2H2O. Journal of Inorganic Biochemistry. 2001; 84(1-2), 23-32.

[4] Thompson, K. H., & Orvig, C.. Vanadium compounds in the treatment of diabetes. Metal ions in biological systems. 2004; 41, 221-252.

[5] Thompson, K. H., & Orvig, C.. Vanadium in diabetes: 100 years from Phase 0 to Phase I. Journal of inorganic biochemistry. 2006; 100(12), 1925-1935.

[6] Ścibior, A., Pietrzyk, Ł., Plewa, Z., & Skiba, A.. Vanadium: Risks and possible benefits in the light of a comprehensive overview of its pharmacotoxicological mechanisms and multi-applications with a summary of further research trends. Journal of Trace Elements in Medicine and Biology. 2020; 61, 126508.

[7] Selvaganapathy, M., & Raman, N.. Pharmacological activity of a few transition metal complexes: a short review. Journal of Chemical Biology & Therapeutics. 2016; 1(02), 1000108.

[8] Rajavel, R., Vadivu, M. S., & Anitha, C.. Synthesis, physical characterization and biological activity of some Schiff base complexes. Journal of Chemistry. 2008; 5, 620-626.

[9] Pepato, M. T., Khalil, N. M., Giocondo, M. P., & Brunetti, I. L.. Vanadium and its complexes: The renewed interest in its biochemistry. Lat. Am. J. Pharm. 2008; 27(3), 468-476.

[10] Abrarin, S., & Ahmed, M. J.. A highly sensitive and selective spectrophotometric method for the determination of vanadium at nanotrace levels in some environmental, biological, soil, food, and pharmaceutical samples using salicylaldehyde-benzoylhydrazone. European Journal of Chemistry. 2020; 11(4), 385-395.

[11] Crans, D. C., Smee, J. J., Gaidamauskas, E., & Yang, L.. The chemistry and biochemistry of vanadium and the biological activities exerted by vanadium compounds. Chemical reviews. 2004; 104(2), 849-902.

[12] Gumerova, N. I., & Rompel, A.. Polyoxometalates in solution: speciation under spotlight. Chemical Society Reviews, 49(21). 2020; 7568-7601.

[13] Rehder, D.. Bioinorganic vanadium chemistry. John Wiley & Sons. 2008

[14] Sumrra, S. H., Habiba, U., Zafar, W., Imran, M., & Chohan, Z. H.. A review on the efficacy and medicinal applications of metal-based triazole derivatives. Journal of Coordination Chemistry. 2020; 73(20-22), 2838-2877.

[15] Selvaganapathy, M., & Raman, N.. Pharmacological activity of a few transition metal complexes: a short review. Journal of Chemical Biology & Therapeutics. 2016; 1(02), 1000108.

[16] Sheela, A., Sarada, N. C., & Vijayaraghavan, R.. A possible correlation between antioxidant and antidiabetic potentials of oxovanadium (IV) complexes. Medicinal Chemistry Research. 2013; 22, 2929-2937.

[17] Jia, C., Guo, Y., & Wu, F. G.. Chemodynamic therapy via fenton and fenton-like nanomaterials: strategies and recent advances. Small. 2022; 18(6), 2103868.

[18] Sharma, B. P., Subin, J. A., Panthi, K. P., Kumar, S., Pandey, A. A., Srivastava, A. K., & Sharma, M. L.. Chemical Synthesis, Characterization, and Computational Investigation of Two Schiff Bases Derived From 3-(2-Hydroxyphenyl)-4-Amino-4H-1, 2, 4-Triazole-5-Thiol and their Corresponding Oxovanadium (IV) Complexes. Journal of Nepal Chemical Society. 2023; 43(2), 70-90.

[19] Eady, R. R.. Current status of structure function relationships of vanadium nitrogenase. Coordination Chemistry Reviews. 2003; 237(1-2), 23-30.

[20] Crans, D. C., Smee, J. J., Gaidamauskas, E., & Yang, L.. The chemistry and biochemistry of vanadium and the biological activities exerted by vanadium compounds. Chemical reviews. 2004; 104(2), 849-902.

[21] Langeslay, R. R., Kaphan, D. M., Marshall, C. L., Stair, P. C., Sattelberger, A. P., & Delferro, M.. Catalytic applications of vanadium: a mechanistic perspective. Chemical reviews. 2018; 119(4), 2128-2191.

[22] Thompson, K. H., Liboiron, B. D., Sun, Y., Bellman, K. D., Setyawati, I. A., Patrick, B. O., ... & Orvig, C.. Preparation and characterization of vanadyl complexes with bidentate maltol-type ligands; in vivo comparisons of anti-diabetic therapeutic potential. JBIC Journal of Biological Inorganic Chemistry. 2003; 8, 66-74.

[23] Yasui, H., Adachi, Y., Katoh, A., & Sakurai, H.. Metallokinetic characteristics of antidiabetic bis (allixinato) oxovanadium (IV)-related complexes in the blood of rat. JBIC Journal of Biological Inorganic Chemistry. 2007; 12, 843-853.

[24] Shechter, Y., Goldwaser, I., Mironchik, M., Fridkin, M., & Gefel, D.. Historic perspective and recent developments on the insulin-like actions of vanadium; toward developing vanadium-based drugs for diabetes. Coordination Chemistry Reviews. 2003; 237(1-2), 3-11.

[25] Bastos, A. M. B., da Silva, J. G., Maia, P. I. D. S., Deflon, V. M., Batista, A. A., Ferreira, A. V., ... & Beraldo, H.. Oxovanadium (IV) and (V) complexes of acetylpyridine-derived semicarbazones exhibit insulin-like activity. Polyhedron. 2008; 27(6), 1787-1794.

[26] Crans, D. C., Smee, J. J., Gaidamauskas, E., & Yang, L.. The chemistry and biochemistry of vanadium and the biological activities exerted by vanadium compounds. Chemical reviews. 2004; 104(2), 849-902.

[27] Sasmal, P. K., Patra, A. K., & Chakravarty, A. R.. Synthesis, structure, DNA binding and DNA cleavage activity of oxovanadium (IV) N-salicylidene-S-methyldithiocarbazate complexes of phenanthroline bases. Journal of inorganic biochemistry. 2008; 102(7), 1463-1472.

[28] Da Silva, J. A., da Silva, J. J. F., & Pombeiro, A. J.. Oxovanadium complexes in catalytic oxidations. Coordination Chemistry Reviews. 2011; 255(19-20), 2232-2248.

[29] Licini, G., Conte, V., Coletti, A., Mba, M., & Zonta, C.. Recent advances in vanadium catalyzed oxygen transfer reactions. Coordination Chemistry Reviews. 2011; 255(19-20), 2345-2357.

[30] Mohebbi, S., Boghaei, D. M., Sarvestani, A. H., & Salimi, A.. Oxovanadium (IV) complexes as homogeneous catalyst aerobic epoxidation of olefins. Applied Catalysis A: General. 2005; 278(2), 263-267.

[31] Zhang, W., Basak, A., Kosugi, Y., Hoshino, Y., & Yamamoto, H.. Enantioselective epoxidation of allylic alcohols by a chiral complex of vanadium: an effective controller system and a rational mechanistic model. Angewandte Chemie International Edition. 2005; 44(28), 4389-4391.

[32] Smith, T. S., & Pecoraro, V. L.. Oxidation of organic sulfides by vanadium haloperoxidase model complexes. Inorganic chemistry. 2002; 41(25), 6754-6760.

[33] Ando, R., Yagyu, T., & Maeda, M.. Characterization of oxovanadium (IV)–Schiff-base complexes and those bound on resin, and their use in sulfide oxidation. Inorganica chimica acta. 2004; 357(8), 2237-2244.

[34] Battistel, E., Tassinari, R., Fornaroli, M., & Bonoldi, L.. Oxidation of benzene by molecular oxygen catalysed by vanadium. Journal of Molecular Catalysis A: Chemical. 2003; 202(1-2), 107-115.

[35] Grivani, G., Delkhosh, S., Fejfarová, K., Dušek, M., & Khalaji, A. D.. Polynuclear oxovanadium (IV) Schiff base complex [VOL2] n (L=(5-bromo-2-hydroxybenzyl-2-furylmethyl) imine): Synthesis, characterization, crystal structure, catalytic properties and thermal decomposition into V2O5 nano-particles. Inorganic Chemistry Communications. 2013; 27, 82-87.

[36] Hoppe, E., Limberg, C., & Ziemer, B.. Mono-and dinuclear oxovanadium (V) calixarene complexes and their activity as oxidation catalysts. Inorganic chemistry. 2006; 45(20), 8308-8317.

[37] Bagherzadeh, M., & Amini, M.. A new vanadium Schiff base complex as catalyst for oxidation of alcohols. Journal of coordination chemistry. 2010; 63(21), 3849-3858.

[38] Figiel, P. J., Sobczak, J. M., & Ziółkowski, J. J.. New efficient aerobic oxidation of some alcohols with dioxygen catalysed by N-hydroxyphtalimide with vanadium co-catalysts. Chemical communications. 2004; (2), 244-245.

[39] Pessoa, J. C., Etcheverry, S., & Gambino, D.. Vanadium compounds in medicine. Coordination chemistry reviews. 2015; 301, 24-48.

[40] Al-Hazmi, G. A., Abou-Melha, K. S., Althagafi, I., El-Metwaly, N., Shaaban, F., Abdul Galil, M. S., & El-Bindary, A. A.. Synthesis and structural characterization of oxovanadium (IV) complexes of dimedone derivatives. Applied Organometallic Chemistry. 2020; 34(8), e5672.

[41] Ebosie, N. P., Ogwuegbu, M. O., Onyedika, G. O., & Onwumere, F. C.. Biological and analytical applications of Schiff base metal complexes derived from salicylidene-4-aminoantipyrine and its derivatives: A review. Journal of the Iranian Chemical Society. 2021; 18(12), 3145-3175.

[42] Damena, T., Zeleke, D., Desalegn, T., Demissie, T. B., & Eswaramoorthy, R.. Synthesis, characterization, and biological activities of novel vanadium (IV) and cobalt (II) complexes. ACS omega. 2022; 7(5), 4389-4404.

[43] Sharma, B. P., Subin, J. A., Marasini, B. P., Adhikari, R., Pandey, S. K., & Sharma, M. L. (2023). Triazole based Schiff bases and their oxovanadium (IV) complexes: Synthesis, characterization, antibacterial assay, and computational assessments. Heliyon, 9(4).

[44] Bagdatli, E., Altuntas, E., & Sayin, U.. Synthesis and structural characterization of new oxovanadium (IV) complexes derived from azo-5-pyrazolone with prospective medical importance. Journal of Molecular Structure. 2017; 1127, 653-661.

[45] Pessoa, J. C., Etcheverry, S., & Gambino, D.. Vanadium compounds in medicine. Coordination chemistry reviews. 2015; 301, 24-48.

[46] Dong, J. F., Jing, B. Q., & Li, L. Z.. Synthesis and crystal structure of an oxovanadium (IV) complex containing L-phenylalanine Schiff base and 1, 10-phenanthroline. Advanced Materials Research. 2014; 1033, 588-591.

[47] MFH, M.. Structural investigation and antibacterial activity of Cu (II), Co (II), Ni (II) and Zn (II) complexes of a Schiff base derived from salicylaldehyde and thiosemicarbazide. Asian Journal of Chemical Sciences. 2020; 6(4), 1-8.

[48] Panchal, P. K., Parekh, H. M., & Patel, M. N.. Preparation, characterization and toxic activity of oxovanadium (IV) mixed-ligand complexes. Toxicological & Environmental Chemistry. 2005; 87(3), 313-320.

[49] Sasmal, P. K., Patra, A. K., Nethaji, M., & Chakravarty, A. R.. DNA cleavage by new oxovanadium (IV) complexes of N-salicylidene α-amino acids and phenanthroline bases in the photodynamic therapy window. Inorganic Chemistry. 2007; 46(26), 11112-11121.

[50] Al-Resayes, S. I., Shakir, M., Abbasi, A., Amin, K. M. Y., & Lateef, A.. Synthesis, spectroscopic characterization and biological activities of N_4O_2 Schiff base ligand and its metal complexes of Co (II), Ni (II), Cu (II) and Zn (II). Spectrochimica acta part A: Molecular and biomolecular spectroscopy. 2012; 93, 86-94.

[51] Arun, V., Sridevi, N., Robinson, P. P., Manju, S., & Yusuff, K. M.. Ni (II) and Ru (II) Schiff base complexes as catalysts for the reduction of benzene. Journal of Molecular Catalysis A: Chemical. 2009; 304(1-2), 191-198.

[52] Kriza, A., Mitu, L., & Stanica, N.. Complex combinations of some" d" transitional metals with the isonicotinoylhydrazone-2-hydroxy-1-naphthaldehyde ligand. Revista de Chimie. 2005; 56(2), 137-140.

[53] Maurya, M. R., Khurana, S., Schulzke, C., & Rehder, D.. Dioxo-and Oxovanadium (V) Complexes of Biomimetic Hydrazone ONO Donor Ligands: Synthesis, Characterisation, and Reactivity. European Journal of Inorganic Chemistry. 2001; 2001(3), 779-788.

[54] Lal, R. A., Chakraborty, M., Chanu, O. B., Choudhury, S., Borthakur, R., Copperfield, S., & Kumar, A.. Synthesis and characterization of heterobimetallic Ni (II)–Zn (II) complexes from bis (2-hydroxy-1-naphthaldehyde) succinoyldihydrazone. Journal of Coordination Chemistry. 2010; 63(7), 1239-1251.

[55] Cichewicz, R. H., & Kouzi, S. A.. Chemistry, biological activity, and chemotherapeutic potential of betulinic acid for the prevention and treatment of cancer and HIV infection. Medicinal research reviews. 2004; 24(1), 90-114.